Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
national blog main
san francisco blog main
san francisco top stories
18
×
sanofi
18
×
boston top stories
life sciences
national top stories
new york blog main
new york top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
fda
cancer
deals
novartis
abbvie
amgen
bristol-myers squibb
celgene
eli lilly
ipo
johnson & johnson
What
bio
roundup
drug
pharmaceutical
cancer
medicines
american
people
companies
continue
healthcare
ipo
known
latest
new
pharma
u.s
week
ahead
alzheimer’s
announced
annual
based
best
ceo
cholesterol
conference
congress
crash
days
deal
debate
disease
executives
gene
group
help
industry
key
kind
Language
unset
Current search:
sanofi
×
" san francisco top stories "
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More